期刊
TRANSFUSION AND APHERESIS SCIENCE
卷 61, 期 2, 页码 -出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.transci.2021.103303
关键词
Autologous transplant; Mobilization; Apheresis; Plerixafor; Algorithm; Cost
类别
The addition of plerixafor (P) to granulocyte colony stimulating factor (G-CSF) during peripheral blood mobilization of hematopoietic stem cells (HSC) increases the number of patients meeting collection goals prior to autologous stem cell transplant (aSCT). However, the use of P is not universally adopted due to cost concerns. This study compares the clinical and financial impacts of using an algorithm-based P mobilization strategy versus its use in all patients. The results show that upfront use of P significantly reduces the number of apheresis days and increases HSC collection yield without increasing overall cost per patient.
Addition of plerixafor (P) to granulocyte colony stimulating factor (G-CSF) during peripheral blood mobilization of hematopoietic stem cells (HSC) increases the number of patients meeting collection goals prior to autologous stem cell transplant (aSCT). However, use of P is not universal among transplant centers due to cost. This study aims to compare clinical and financial impacts of using an algorithm-based P mobilization strategy versus use in all patients. This was a single center, retrospective analysis of adult patients with myeloma or amyloidosis receiving aSCT who received apheresis of their HSC between 3/1/2017 and 3/1/2019. Patients prior to 3/1/ 2018 were classified as receiving P per algorithm and those after this date were classified as up-front P. For the per-algorithm group, P was given for a pre-apheresis CD34+ cell count of <20 cells/mu L on mobilization day 5 and patients returned on day 6 for apheresis. Of the 129 patients included, 55 received P per-algorithm and 74 received up-front P. There was a reduction in median number of apheresis days (1.5 vs 1 day, p < 0.001) and an increase in median number of CD34+ cells collected (6.6 vs 8.5 x 10(6) cells/kg, p < 0.001) with up-front P. Upfront P increased drug cost but reduced apheresis costs, which resulted in a net savings of $121 per patient in total mobilization costs. These findings suggest that use of up-front P for mobilization significantly reduces apheresis days and increases HSC collection yield without increasing overall cost per patient.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据